Collegium Pharmaceutical, Inc. (COLL) vs Solid Biosciences Inc. (SLDB)
A side-by-side comparison of Collegium Pharmaceutical, Inc. and Solid Biosciences Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
COLL
Collegium Pharmaceutical, Inc.
$21.88HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
SLDB
Solid Biosciences Inc.
$6.92HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — COLL vs SLDB
growth of $100 · dividends reinvested · last 9yCOLL -12.2% (-1.4%/yr)SLDB -97.9% (-35.0%/yr)COLL compounded faster over this window
Log scale — wide-divergence pair
COLL SLDB
COLL vs SLDB: by the numbers
- •COLL is the larger company ($710M vs $681M market cap).
- •COLL is profitable (5.93% net margin) while SLDB runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | COLL | SLDB |
|---|---|---|
| P/E ratio | 17.65 | N/A |
| PEG ratio | 0.99 | N/A |
| P/S ratio | 0.88 | N/A |
| P/B ratio | 2.28 | 1.82 |
| EV / EBITDA | 2.84 | N/A |
| FCF yield | 46.26% | N/A |
Profitability
| Metric | COLL | SLDB |
|---|---|---|
| Gross margin | 60.02% | 0.00% |
| Operating margin | 19.61% | 0.00% |
| Net margin | 5.93% | 0.00% |
| ROE | 15.36% | -55.36% |
| ROIC | 6.11% | -54.12% |
Growth (annualized)
| Metric | COLL | SLDB |
|---|---|---|
| Revenue CAGR (5Y) | 19.91% | N/A |
| EPS CAGR (5Y) | 20.48% | N/A |
| FCF CAGR (5Y) | 26.38% | N/A |
| Total return CAGR (5Y) | 2.15% | -27.50% |
Frequently asked
- Is COLL or SLDB more profitable?
- COLL runs the higher net margin — COLL at 5.93% versus SLDB at 0.00%.
- How have COLL and SLDB total returns compared?
- Over the past 5 years, COLL delivered 2.15% and SLDB delivered -27.50% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Collegium Pharmaceutical P/E ratioCollegium Pharmaceutical ROESolid Biosciences ROECollegium Pharmaceutical operating marginSolid Biosciences operating marginCollegium Pharmaceutical revenue growthSolid Biosciences revenue growthCollegium Pharmaceutical free cash flowSolid Biosciences free cash flow
Collegium Pharmaceutical & Solid Biosciences appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.